## Abstract Results are presented of Epstein‐Barr virus‐specific serologic tests for seven Alaskan Native patients with nasopharyngeal carcinoma (NPC) from whom serum had been collected 2–10 years before diagnosis and up to 6 years after diagnosis. The pre‐illness antibody spectra and titers of the
Native early antigen of Epstein–Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma
✍ Scribed by Dewi K. Paramita; Jajah Fachiroh; Wayan T. Artama; Eric van Benthem; Sofia M. Haryana; Jaap M. Middeldorp
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 248 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The Epstein–Barr virus (EBV) early antigen (EA) complex consists of multiple proteins with relevance for diagnosis of acute, chronic and malignant EBV related diseases, including nasopharyngeal carcinoma (NPC). In a recent study, it was found that the molecular diversity of EBV‐specific IgG and IgA antibody responses in NPC patients and demonstrated that these reflect independent B‐cell triggering leading to distinct EBV antigen‐recognition profiles. The fine‐specificity of NPC‐related IgG and IgA responses was explored further against defined recombinant and synthetic EBV‐EA antigens using immunofluorescence, immunoblot and ELISA techniques and determined their diagnostic value in a large panel of sera from NPC (n = 154), non‐NPC tumor patients (n = 133), acute mononucleosis patients (n = 70) and healthy EBV carriers (n = 259). Individual recombinant EBV‐EA markers yielded sensitivity/specificity values not exceeding 86%, whereas selected EA‐specific peptide epitopes were rather poorly recognized by IgG and IgA antibodies in NPC sera. Surprisingly, we found that a “low salt” native EA‐protein extract reproducibly prepared from purified nuclei of EA‐induced HH514 cells, and containing characteristic EA(D)‐polypeptides, such as p47‐54 (BMRF1), p138 (BALF2), p55‐DNAse (BGLF5), and p65‐TK (BXLF1), but without viral capsid (VCA) or nuclear antigen (EBNA) reactivity, gave highest sensitivity (90.4%) and specificity (95.5%) values for NPC diagnosis in both IgG and IgA ELISA. The data support further the notion that EBV‐EA reactive IgG and IgA antibodies in NPC patients are directed against distinct conformational and—in part—linear epitopes on EBV‐specific proteins, barely recognized in other EBV‐related syndromes. The use of a defined native EBV EA‐specific antigen opens the way to further improve serological diagnosis of NPC. J. Med. Virol. 79:1710–1721, 2007. © 2007 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract An immunoautoradiographic method was used for the detection of EB virus lgA/EA antibody in sera from NPC patients and other control groups. Ninety‐six percent of NPC patients had IgA/EA antibody with a high titer of GMT. The positive rates of IgA/EA antibody in patients with malignant t
We have previously shown that high levels of antibody to Epstein-Barr virus (EBV)-specific DNase may be a useful marker for the early diagnosis of nasopharyngeal carcinoma (NPC). Sera from 3,368 males in an area with a high risk for the development of NPC were examined for the presence of antibody t
## Abstract Serological tests for Epstein‐Barr virus (EBV) have been used for many years as diagnostic predictors of nasopharyngeal carcinoma. It has been shown previously that the conventional immunofluorescence assay has a limited diagnostic value, especially in young patients from North African
## Abstract ## BACKGROUND Serologic measurement of antibodies to Epstein–Barr virus (EBV) immunoglobulin A/viral capsid antigen (IgA/VCA) and early antigen (IgA/EA) has been used widely to screen for nasopharyngeal carcinoma (NPC) in China. Recently, it was found that plasma EBV DNA concentration
The authors thank Drs. Anthony J. Janckila and Lung T. Yam of the University of Louisville, Louisville, Kentucky, for their criticism of this article. They also would like to thank Miss Su-Huei Lee for her excellent technique for in situ hybridization and immunohistochemical stainings.